Biotech's Challenge: Balancing R&D with Shareholder Returns
NEW YORK – An age-old problem with the business-as-usual model in the biotech market is that the objectives of the principal stakeholders are integrally at odds with one another. The executives, investors and researchers who make things happen in the drug development world all want to see their drugs approved or they want to experience an exit strategy come to fruition, but they have different ideologies on achieving that goal.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter